We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mixed Chimeric Transplantation for Primary Amyloidosis

This study has been withdrawn prior to enrollment.
(Closed, never started.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00186095
First Posted: September 16, 2005
Last Update Posted: October 10, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Stanford University
  Purpose
To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.

Condition Intervention
Amyloidosis Procedure: autologous followed by nonmyeloablative allogeneic transplant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Mixed Chimeric Transplantation for Primary Amyloidosis

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.

Secondary Outcome Measures:
  • Toxicity of therapy
  • Changes in marrow and serum abnormalities
  • Improvement in end-organ function.

Estimated Enrollment: 45
Study Start Date: December 2000
Estimated Study Completion Date: September 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • primary amyloidosis
  • adequate organ function
  • matched sibling donor

Exclusion Criteria:

  • evidence of multiple myeloma
  • HIV positive
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00186095


Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Keith Stockerl-Goldstein, MD Stanford University
  More Information

ClinicalTrials.gov Identifier: NCT00186095     History of Changes
Other Study ID Numbers: BMT129
First Submitted: September 13, 2005
First Posted: September 16, 2005
Last Update Posted: October 10, 2007
Last Verified: October 2007

Keywords provided by Stanford University:
Amyloidosis
nonmyeloablative
hematopoietic
cell transplantation

Additional relevant MeSH terms:
Amyloidosis
Proteostasis Deficiencies
Metabolic Diseases